Liang-Wen Hang1,2,3, Chi-Fung Chen4, Chang-Bi Wang4, Trong-Neng Wu4,5, Wen-Miin Liang6,7, Tzu-Chieh Chou8,9. 1. Department of Respiratory Therapy, College of Health Care, China Medical University, Taichung, Taiwan. 2. Sleep Medicine Center, Department of Pulmonary and Critical Care Medicine, China Medical University Hospital, Taichung, Taiwan. 3. Department of Healthcare Administration, Asia University, Taichung, Taiwan. 4. Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan. 5. Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan. 6. Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan. wmliang.cmu@gmail.com. 7. Graduate Institute of Biostatistics, College of Public Health, China Medical University, Taichung, Taiwan. wmliang.cmu@gmail.com. 8. Department of Public Health, College of Public Health, China Medical University, Taichung, Taiwan. choutc@mail.cmu.edu.tw. 9. Department of Health Risk Management, College of Public Health, China Medical University, Taichung, Taiwan. choutc@mail.cmu.edu.tw.
Abstract
PURPOSE: Studies on the association between continuous positive airway pressure (CPAP) treatment and liver diseases such as non-alcoholic fatty liver disease (NAFLD) and cirrhosis in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) are limited. To the best of our knowledge, none exists that makes use of a national database in an Asian population. This study aims to evaluate the effects of CPAP treatment on patients with these two disorders in a retrospective, population-based study in Taiwan. METHODS: Using the Taiwan National Health Insurance claims database, this study collected the data of OSAHS patients diagnosed between 2000 and 2008 and divided them into CPAP treatment and non-CPAP treatment groups. All subjects were followed up until 2010. Liver disease incidence and risk were calculated. RESULTS: The CPAP group had a lower cumulative incidence rate of developing liver disease than the non-CPAP group within the observation periods (p < 0.001). After adjusting for age, gender, urbanization level, and comorbidities, the CPAP treatment group showed a lower risk of developing liver disease compared with the non-CPAP treatment group (sub-aHR of 0.66 (95% CI 0.55-0.80), p < 0.001). CONCLUSIONS: Our observations suggest that CPAP treatment may play an important role to delay the progression of liver disease in OSAHS patients and decreases the incidence of liver disease among OSAHS patients. Thus, CPAP therapy may be a feasible way to decrease the risk of liver disease among patients with OSAHS.
PURPOSE: Studies on the association between continuous positive airway pressure (CPAP) treatment and liver diseases such as non-alcoholic fatty liver disease (NAFLD) and cirrhosis in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) are limited. To the best of our knowledge, none exists that makes use of a national database in an Asian population. This study aims to evaluate the effects of CPAP treatment on patients with these two disorders in a retrospective, population-based study in Taiwan. METHODS: Using the Taiwan National Health Insurance claims database, this study collected the data of OSAHSpatients diagnosed between 2000 and 2008 and divided them into CPAP treatment and non-CPAP treatment groups. All subjects were followed up until 2010. Liver disease incidence and risk were calculated. RESULTS: The CPAP group had a lower cumulative incidence rate of developing liver disease than the non-CPAP group within the observation periods (p < 0.001). After adjusting for age, gender, urbanization level, and comorbidities, the CPAP treatment group showed a lower risk of developing liver disease compared with the non-CPAP treatment group (sub-aHR of 0.66 (95% CI 0.55-0.80), p < 0.001). CONCLUSIONS: Our observations suggest that CPAP treatment may play an important role to delay the progression of liver disease in OSAHSpatients and decreases the incidence of liver disease among OSAHSpatients. Thus, CPAP therapy may be a feasible way to decrease the risk of liver disease among patients with OSAHS.
Entities:
Keywords:
CPAP treatment; Cohort; Liver disease; OSAHS; Population-based study
Authors: Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks Journal: J Clin Invest Date: 2005-05 Impact factor: 14.808
Authors: David S Hui; Qing Shang; Fanny W Ko; Susanna S Ng; Cheuk-Chun Szeto; Jenny Ngai; Alvin H Tung; Kin-Wang To; Tat-On Chan; Cheuk-Man Yu Journal: Respir Res Date: 2012-03-16
Authors: Valerio Rosato; Mario Masarone; Marcello Dallio; Alessandro Federico; Andrea Aglitti; Marcello Persico Journal: Int J Environ Res Public Health Date: 2019-09-14 Impact factor: 3.390